CA2416676A1 - Acides nucleiques comprenant des regions du promoteur peg-3 du rat et leurs utilisations - Google Patents

Acides nucleiques comprenant des regions du promoteur peg-3 du rat et leurs utilisations Download PDF

Info

Publication number
CA2416676A1
CA2416676A1 CA002416676A CA2416676A CA2416676A1 CA 2416676 A1 CA2416676 A1 CA 2416676A1 CA 002416676 A CA002416676 A CA 002416676A CA 2416676 A CA2416676 A CA 2416676A CA 2416676 A1 CA2416676 A1 CA 2416676A1
Authority
CA
Canada
Prior art keywords
cell
gene
peg
cells
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002416676A
Other languages
English (en)
Inventor
Paul B. Fisher
Zao-Zhong Su
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Columbia University in the City of New York
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/621,781 external-priority patent/US6737523B1/en
Application filed by Individual filed Critical Individual
Publication of CA2416676A1 publication Critical patent/CA2416676A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne un acide nucléique isolé comprenant un promoteur PEG-3 possédant la séquence de nucléotides commençant par guanosine (G) dans la position -270 et finissant par cytosine (C) dans la position +194 de SEQ ID NO:1. Elle concerne également un procédé servant à identifier un agent modulant l'activité du promoteur PEG-3 dans une cellule. Elle concerne également un procédé servant à traiter le cancer chez un patient.
CA002416676A 2000-07-21 2001-07-20 Acides nucleiques comprenant des regions du promoteur peg-3 du rat et leurs utilisations Abandoned CA2416676A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/621,781 2000-07-21
US09/621,781 US6737523B1 (en) 1998-03-20 2000-07-21 Nucleic acids comprising regions of the rat PEG-3 promoter that display elevated expression in human cancer cells and uses thereof
PCT/US2001/023099 WO2002008242A1 (fr) 2000-07-21 2001-07-20 Acides nucleiques comprenant des regions du promoteur peg-3 du rat et leurs utilisations

Publications (1)

Publication Number Publication Date
CA2416676A1 true CA2416676A1 (fr) 2002-01-31

Family

ID=24491606

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002416676A Abandoned CA2416676A1 (fr) 2000-07-21 2001-07-20 Acides nucleiques comprenant des regions du promoteur peg-3 du rat et leurs utilisations

Country Status (5)

Country Link
EP (1) EP1309603A4 (fr)
JP (1) JP2004520006A (fr)
AU (1) AU2001277094A1 (fr)
CA (1) CA2416676A1 (fr)
WO (1) WO2002008242A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2482904A1 (fr) * 2002-04-18 2003-10-23 Lynkeus Biotech Gmbh Moyens et procedes pour la modulation specifique de genes cibles dans le snc et l'oeil, et procedes pour leur identification
US7148342B2 (en) 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
WO2005070948A1 (fr) 2004-01-23 2005-08-04 Intronn, Inc. Correction de defauts genetiques lies a l'alpha-1-antitrypsine par transepissage d'arn a mediation par spliceosome
US7449565B2 (en) 2005-01-21 2008-11-11 The Trustees Of Columbia University In The City Of New York Chimeric tumor suppressor gene and protein
JP5832293B2 (ja) 2008-12-04 2015-12-16 オプコ ファーマシューティカルズ、エルエルシー 血管新生促進ｖｅｇｆイソ型を選択的に抑制する組成物および方法
WO2012058522A2 (fr) * 2010-10-28 2012-05-03 Virginia Commonwealth University Imagerie du cancer au moyen d'une thérapie : la théranostique

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6472520B2 (en) * 1997-03-21 2002-10-29 The Trustees Of Columbia University In The City Of New York Rat PEG-3 promoter
US6146877A (en) * 1997-03-21 2000-11-14 The Trustees Of Columbia University In The City Of New York Identification of the progression elevated gene-3 and uses thereof

Also Published As

Publication number Publication date
EP1309603A1 (fr) 2003-05-14
AU2001277094A1 (en) 2002-02-05
JP2004520006A (ja) 2004-07-08
WO2002008242A1 (fr) 2002-01-31
EP1309603A4 (fr) 2004-07-28

Similar Documents

Publication Publication Date Title
US6737523B1 (en) Nucleic acids comprising regions of the rat PEG-3 promoter that display elevated expression in human cancer cells and uses thereof
Wang et al. Inhibition of DNA topoisomerase IIα gene expression by the p53 tumor suppressor
AU715526B2 (en) Novel nucleic acid molecules comprising the prostate specific antigen (PSA) promoter and uses thereof
US7067317B2 (en) Regulation of angiogenesis with zinc finger proteins
FI113787B (fi) Vektori geenituotteen ilmentämiseksi solussa
Chiou et al. p300 binding by E1A cosegregates with p53 induction but is dispensable for apoptosis
Wu et al. Reduction of cytosolic p27Kip1 inhibits cancer cell motility, survival, and tumorigenicity
Serrano et al. Inhibition of ras-induced proliferation and cellular transformation by p16INK4
WO1996014875A9 (fr) Nouvelles molecules d'acide nucleique comportant un antigene prostatique specifique et leurs usages
Heinrich et al. The c-Jun dimerization protein 2 inhibits cell transformation and acts as a tumor suppressor gene
Su et al. Potent antitumoral efficacy of a novel replicative adenovirus CNHK300 targeting telomerase-positive cancer cells
Müller-Tidow et al. Cyclin A1 directly interacts with B-myb and cyclin A1/cdk2 phosphorylate B-myb at functionally important serine and threonine residues: tissue-specific regulation of B-myb function
Kumagai et al. Eradication of Myc-overexpressing small cell lung cancer cells transfected with herpes simplex virus thymidine kinase gene containing Myc-Max response elements
Pierantoni et al. A truncated HMGA1 gene induces proliferation of the 3T3-L1 pre-adipocytic cells: a model of human lipomas
Antonson et al. Myc inhibits CCAAT/enhancer‐binding protein α‐gene expression in HIB‐1B hibernoma cells through interactions with the core promoter region
CA2416676A1 (fr) Acides nucleiques comprenant des regions du promoteur peg-3 du rat et leurs utilisations
AU2001274026B2 (en) Protein complexes and assays for screening anti-cancer agents
US7229822B1 (en) Melanoma differentation associated gene-5 and vectors and cells containing same
US6841362B1 (en) Melanoma differentiation associated gene-7 promoter and uses thereof
US6110702A (en) PSA positive regulating (PSAR) sequences and uses thereof
US6982148B2 (en) Progressive elevated gene-3 (PEG-3) induces aggressive cancer phenotype and regulates angiogenesis
Alvarez-Salas et al. YY-1 and c-Jun transcription factors participate in the repression of the human involucrin promoter
Chuang et al. The Epstein–Barr virus nuclear antigen‐1 may act as a transforming suppressor of the HER2/neu oncogene
WO1997035993A9 (fr) Sequences de regulation positive de l'antigene prostatique specifique et utilisations de ces sequences
Hsu et al. The p53 codon 249 mutant–derived from human functional adrenal tumors–can modify the cell shape of normal adrenocortical transfected cells

Legal Events

Date Code Title Description
FZDE Dead